Alterations in gut microbiome are associated with the onset of multiple sclerosis: an Italian pivotal study by Rolla, S et al.
14 December 2021
AperTO - Archivio Istituzionale Open Access dell'Università di Torino
Original Citation:




(Article begins on next page)
Anyone can freely access the full text of works made available as "Open Access". Works made available under a
Creative Commons license can be used according to the terms and conditions of said license. Use of all other works
requires consent of the right holder (author or publisher) if not exempted from copyright protection by the applicable law.
Availability:
SAGE PUBLICATIONS LTD
This is a pre print version of the following article:
This version is available http://hdl.handle.net/2318/1757447 since 2020-10-01T15:22:14Z
Abstract: P770 
Type: Poster Sessions 
Abstract Category: Pathology and pathogenesis of MS - Environmental factors 
Background: The gut microbiome consists of a highly diverse ecologic community of microorganisms and plays an 
important role in immune functions: commensal bacteria are indeed necessary for the development and maintenance of a 
healthy immune system. Imbalance in the gut microbiota composition has been suggested as a risk factor for Multiple 
Sclerosis (MS: animal studies demonstrated that alteration of the gut microbiota could effectively modulate the immune-
mediated demyelination through the generation of encephalithogenic T-helper (Th)17 cells or protective T-regulatory (Treg) 
cells in the gut followed by their transmigration in the periphery and in the central nervous system. 
Aims: we investigated whether alteration in the composition of the gut microbiota, in terms of species richness, distribution 
and functional potential, could be associated with the onset of MS, namely the first episode of demyelinization, and its 
immune system alteration in a small Italian cohort. 
Methods: Stool and blood samples were collected from 18 newly diagnosed MS patients and 18 Healthy Volunteers (HV) 
highly matched for age, sex, diet and lifestyle. DNA isolated from stools were subjected to shotgun metagenomic 
sequencing strategy in order to discover the microbiota composition as well as the microbial function and to correlate it 
with fecal metabolites, analyzed with Gas chromatography-mass spectrometry, and with Th17 and Treg cells, analyzed by 
FACS, in the peripheral blood (PB). 
Results: At the onset of MS, gut microbiome structure of patients is clearly different from that of HV and displayed a lower 
species richness and lower number of taxa. It was characterized by a reduction in abundance of genera belonging to 
Butyrate-producing bacteria that correlated with a lower butyrate amount in the feces and with the decrease of Treg cells 
producing IL-10 in the PB of MS patients compared to HV. 
Conclusions: our data indicate that gut microbial dysbiosis exist at the onset of MS and could be associated with the 
autoimmune response in the periphery, highlighting the importance of gut microbiome in the etiology of MS. 
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